Niagen Bioscience
NAGE
61 hedge funds and large institutions have $32.7M invested in Niagen Bioscience in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 10 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 14
0.01% less ownership
Funds ownership: 17.33% → 17.32% (-0.01%)
5% less funds holding
Funds holding: 64 → 61 (-3)
20% less capital invested
Capital invested by funds: $40.9M → $32.7M (-$8.12M)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$84.8K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$78K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$60.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$60.3K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$58.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OC
Oppenheimer & Co
New York
|
-$148K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$128K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$93K |
| 4 |
Jane Street
New York
|
-$90K |
| 5 |
WSTAM
Wilbanks Smith & Thomas Asset Management
Norfolk,
Virginia
|
-$86K |
NAGE Hedge Fund Activity: Q4 2018 in Review
61 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q4 2018, worth a combined $32.7M — down 20% from $40.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of NAGE and 7 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 16 added.
The largest buyer was Bank of New York Mellon, adding an estimated $84.8K. The largest seller was Oppenheimer & Co, cutting an estimated $148K.
- 61 institutional investors held Niagen Bioscience (NAGE) as of Q4 2018, down from 64 in Q3 2018.
- Funds reported $32.7M of Niagen Bioscience stock for Q4 2018, down 20% quarter-over-quarter.
- 7 funds opened new Niagen Bioscience positions in Q4 2018 and 10 closed out, a net change of -3 holders.
- The largest Niagen Bioscience buyer in Q4 2018 was Bank of New York Mellon, an estimated $84.8K added.
- The largest Niagen Bioscience seller in Q4 2018 was Oppenheimer & Co, an estimated $148K sold.
Based on aggregated 13F filings for Q4 2018.